Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Barclays PLC from $230.00 to $200.00. They now have an "overweight" rating on the stock.
Jazz Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $222.00 price target on the stock.